Immatics N.V.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $IMTX in the last 7 days.
No SEC Form 4 filings for $IMTX in the last 30 days.
See all $IMTX insider activity →Stifel initiated coverage of Immatics with a Buy rating and $15 price target, implying 119.6% upside from the Oct 13 close. The firm cites positive clinical trial outlook and strong market positioning for anzu-cel therapy, expected to launch in early 2028.
PERCEPTIVE ADVISORS LLC purchased 863,060 indirectly-held shares of Immatics N.V. (IMTX) at $8.69 ($7.50M total) on 2026-08-26. Filed jointly with EDELMAN JOSEPH (Director) and PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Director).
Immatics (IMTX) raised $161.1 million via an equity offering, including 15.5 million shares and pre-funded warrants. Proceeds will fund R&D, manufacturing, and potential commercialization of its oncology pipeline, as well as general corporate purposes.
Recent IMTX coverage spans corporate actions, market movers and financial news.
Analyst initiation and elevated price target suggest strong upside potential for Immatics.
The insider purchase suggests confidence from management and may support short-term upside.
The fresh capital strengthens the balance sheet and may support upcoming oncology trial funding, potentially boosting the stock.
Capital raise funds pipeline but dilutes existing shareholders.
The capital raise dilutes existing shareholders but provides significant cash for development.
AlphAI scores every news story that mentions IMTX with an AI model for sentiment and relevance, and aggregates insider trades from Immatics N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel initiated coverage of Immatics with a Buy rating and $15 price target, implying 119.6% upside from the Oct 13 close. The firm cites positive clinical trial outlook and strong market positioning for anzu-cel therapy, expected to launch in early 2028.
1 min readPERCEPTIVE ADVISORS LLC purchased 863,060 indirectly-held shares of Immatics N.V. (IMTX) at $8.69 ($7.50M total) on 2026-08-26. Filed jointly with EDELMAN JOSEPH (Director) and PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Director).
1 min readImmatics (IMTX) raised $161.1 million via an equity offering, including 15.5 million shares and pre-funded warrants. Proceeds will fund R&D, manufacturing, and potential commercialization of its oncology pipeline, as well as general corporate purposes.
2 min readTenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.
3 min readImmatics N.V. (IMTX) plans to raise $150 million through a public offering, selling 12.95 million shares at $8.69 each and warrants for 4.32 million shares. The offering is expected to close August 26, 2026, with underwriters having a 30-day option to buy additional shares. IMTX stock is up 10.82% in pre-market trading.
2 min readNayax Ltd (NYAX) agreed to acquire IPS Group Inc. for $350M in cash, sending its shares up 13.9%. Other stocks gaining include Capricor Therapeutics (CAPR), Rezolve AI (RZLV), and Moderna (MRNA), which rose 9.9% following analyst upgrades. Marvell Technology (MRVL) also gained 6.5% after price target increases.
2 min readSeveral biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readImmatics NV (IMTX) stock rose 4.7% to $9.10 in pre-market trading after announcing a $150M share offering. Goldman Sachs reiterated its Buy rating, citing strong analyst consensus and a $17–$19 price target. The company also reported Q2 2026 results, boosting investor confidence. The NASDAQ's rise provided additional support.
1 min readImmatics N.V. (NASDAQ: IMTX) reported Q2 2026 results and a SUPRAME Phase 3 update for anzu-cel (IMA203) in advanced melanoma. PFS events are occurring more slowly than modeled, so the company will use a single streamlined final PFS analysis and add ~90 patients to strengthen OS. SUPRAME final PFS topline is expected H1 2027, with BLA submission in 2027. Cash: $448.2M as of June 30, 2026.
6 min readImmatics N.V. (IMTX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and six-month period ended June 30, 2026, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as
2 min read
